Nuveen’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Nuveen’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-58,887	Closed	-$97K	–	3627
2022 Q1	$97K	Hold	58,887	–	–	﹤0.01%	3247
2021 Q4	$177K	Hold	58,887	–	–	﹤0.01%	3249
2021 Q3	$343K	Sell	58,887 -19,953	-25%	-$124K	﹤0.01%	3233
2021 Q2	$586K	Buy	78,840 +13,900	+21%	+$98.5K	﹤0.01%	3145
2021 Q1	$526K	Sell	64,940 -1,371	-2%	-$14.9K	﹤0.01%	3089
2020 Q4	$603K	Buy	66,311 +9,085	+16%	+$74.5K	﹤0.01%	2991
2020 Q3	$633K	Buy	57,226 +287	+0.5%	+$1.99K	﹤0.01%	2865
2020 Q2	$423K	Buy	56,939 +27,759	+95%	+$186K	﹤0.01%	2962
2020 Q1	$179K	Buy	+29,180	New	+$190K	﹤0.01%	3009

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Nuveen's KLDO Position: Q2 2022 in Review

Nuveen sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 58,887 shares — an estimated $97K sold.

Nuveen first reported a position in KLDO in Q1 2020 and held it in 9 quarters. The position peaked at $633K in Q3 2020. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

Nuveen reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Nuveen sold 58,887 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $97K.
Nuveen first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2020 and held it in 9 quarters.
Nuveen's Kaleido Biosciences, Inc. Common Stock position peaked at $633K in Q3 2020.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.